Order Summary

In order to access content on the FENIX Marketplace, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

By selecting this, I agree to receive emails from fenix.group.

You will be granted access to your FENIX Library to view the full article after sign up.
RETURN TO HOME
$0
Dual/triple agonist, GLP-1RA

Lilly oral dual agonist comments @ BAML

Here is a brief preview of this blast: Lilly’s president of diabetes, Enrique Conterno, participated in a fireside chat at the 2019 BAML Conference (webcast link here). For what is believed to be the first time, Conterno commented that Lilly is looking to develop an oral GIP/GLP-1 based on its current understanding from tirzepatide (injectable GIP/GLP-1) and having a non-peptidic oral GLP-1RA (OWL833) licensed from Chugai (Ph1 ready; previous FENIX insight).  Below, FENIX provides thoughts on Lilly's oral GLP-1 development strategy.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.